百健暂停多发性硬化症试验部分环节；默克公布更多Enflonsia数据。
Biogen stops part of an MS trial; Merck reports more Enflonsia data
生命科学资讯
生物技术与制药领域的最新动态
赛诺菲扩大在印业务；施达制药向沙特投资1亿美元。
Sanofi to expand in India; Stada invests $100M in Saudi Arabia
Hims以2.4亿美元预付款收购澳大利亚Eucalyptus，加速全球扩张。
Hims to buy Australia’s Eucalyptus for $240M upfront in global push
Altesa raises $75M for oral respiratory med
J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug
强生暂停招募AC免疫阿尔茨海默症药物中期试验患者。
J&J pauses patient recruitment in mid-stage trial of AC Immune’s Alzheimer’s drug
临床AI初创公司Kintsugi为何关停
Why clinical AI startup Kintsugi shut down
参议院卫生委员会主席规划FDA未来改革蓝图
Senate health committee chair plots future FDA changes
特朗普推动药品定价协议立法，制药行业谈判结束
Pharma is done negotiating as Trump pushes to codify deals
强生在宾夕法尼亚州投资10亿美元建设新细胞疗法基地。
J&J pours $1B into new cell therapy site in Pennsylvania
查尔斯河公司强调，随着关税不确定性消退，需求增长显著。
Charles River highlights increase in demand as tariff uncertainties fade
更新：诺华与Unnatural Products签署大环化合物合作协议
Updated: Novartis signs macrocyclic deal with Unnatural Products
诺华与Unnatural Products签署大环化合物协议，预付款达1亿美元。
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Moderna流感疫苗申请在FDA经历非典型路径后出现逆转。
Reversal on Moderna's flu application follows atypical path through FDA
礼来Zepbound与Taltz联合疗法公布银屑病与减重数据；诺华强化Rhapsido疗效结果。
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Faeth与Sensei合并上市，通过股票销售净赚2亿美元
Faeth goes public in merger with Sensei, nets $200M in stock sale
FDA转变立场，将审查莫德纳流感疫苗。
FDA reverses course, will review Moderna’s flu vaccine
礼来以1亿美元预付款获得CSL的IL-6免疫炎症抗体许可。
Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront
Paragon新生物技术公司Korsana挑战阿尔茨海默病，与罗氏一较高下。
Paragon's new biotech Korsana tackles Alzheimer's like Roche
Paragon最新生物技术将尝试像罗氏一样延缓阿尔茨海默病进程——Endpoints新闻
Paragon's latest biotech will try to slow Alzheimer's like Roche - Endpoints News